The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2017 | The biases of using bone marrow biopsies for multiple myeloma
A full understanding of the methods available for diagnosis, prognosis and stratification are required in order to choose the optimal method depending on the cirumstances. In this video, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Jens Lohr, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the selection and site bias of using bone marrow biopsies for multiple myeloma. Dr Lohr also questions how representative liquid biopsies are.
